Cargando…

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects

Omecamtiv mecarbil (OM), a novel cardiac myosin activator, is being evaluated for the treatment of heart failure with reduced ejection fraction. In vitro studies demonstrate OM as a substrate and inhibitor of P‐glycoprotein (P‐gp), which can result in drug‐drug interactions. Two phase 1, open‐label...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trivedi, Ashit, Sohn, Winnie, Hsu, Cheng‐Pang, Jafarinasabian, Pegah, Zhang, Hanze, Hutton, Shauna, Flach, Stephen, Abbasi, Siddique, Dutta, Sandeep, Lee, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293137/ https://www.ncbi.nlm.nih.gov/pubmed/34634185 http://dx.doi.org/10.1002/cpdd.1028

Ejemplares similares

Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
por: Trivedi, Ashit, et al.
Publicado: (2021)

Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model
por: Trivedi, Ashit, et al.
Publicado: (2021)

Allosteric modulation of cardiac myosin dynamics by omecamtiv mecarbil
por: Hashem, Shaima, et al.
Publicado: (2017)

Effects of omecamtiv mecarbil and mavacamten in isolated human atrium
por: Abella, Lina Maria Rayo, et al.
Publicado: (2022)

Cardioprotective Properties of Omecamtiv Mecarbil against Ischemia and Reperfusion Injury
por: Stroethoff, Martin, et al.
Publicado: (2019)

Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study
por: Felker, G. Michael, et al.
Publicado: (2020)

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
por: Kaplinsky, Edgardo, et al.
Publicado: (2018)

Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans
por: Fülöp, Gábor Á., et al.
Publicado: (2021)

Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (−)‐noradrenaline
por: Dashwood, Alexander, et al.
Publicado: (2021)

Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil
por: Planelles-Herrero, Vicente J., et al.
Publicado: (2017)

Orthophosphate increases the efficiency of slow muscle-myosin isoform in the presence of omecamtiv mecarbil
por: Governali, Serena, et al.
Publicado: (2020)

Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
por: Metra, Marco, et al.
Publicado: (2022)

Effects of omecamtiv mecarbil on calcium‐transients and contractility in a translational canine myocyte model
por: Gao, BaoXi, et al.
Publicado: (2020)

Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management
por: Patel, Pooja H, et al.
Publicado: (2021)

cMyBPC phosphorylation modulates the effect of omecamtiv mecarbil on myocardial force generation
por: Mamidi, Ranganath, et al.
Publicado: (2021)

Effects of omecamtiv mecarbil on the contractile properties of skinned porcine left atrial and ventricular muscles
por: Nakanishi, Tomohiro, et al.
Publicado: (2022)

Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis
por: Alqatati, Fadel, et al.
Publicado: (2022)

Altered Left Ventricular Rat Gene Expression Induced by the Myosin Activator Omecamtiv Mecarbil
por: El Oumeiri, Bachar, et al.
Publicado: (2023)

Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats
por: El-Oumeiri, Bachar, et al.
Publicado: (2018)

Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke
por: Woody, Michael S., et al.
Publicado: (2018)

Omecamtiv mecarbil lowers the contractile deficit in a mouse model of nebulin-based nemaline myopathy
por: Lindqvist, Johan, et al.
Publicado: (2019)

Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca(2+) levels
por: Ráduly, Arnold Péter, et al.
Publicado: (2023)

The myosin activator omecamtiv mecarbil improves wall stress in a rat model of chronic aortic regurgitation
por: El Oumeiri, Bachar, et al.
Publicado: (2021)

Comprehensive in vitro pro‐arrhythmic assays demonstrate that omecamtiv mecarbil has low pro‐arrhythmic risk
por: Qu, Yusheng, et al.
Publicado: (2021)

Omecamtiv mecarbil treatment improves post-resuscitation cardiac function and neurological outcome in a rat model
por: Wu, Shih-Ni, et al.
Publicado: (2022)

Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action
por: Parikh, Jaimit, et al.
Publicado: (2021)

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials
por: Teerlink, John R., et al.
Publicado: (2020)

Characterization of Stimulatory Action on Voltage-Gated Na(+) Currents Caused by Omecamtiv Mecarbil, Known to Be a Myosin Activator
por: Ting, Chih-Yu, et al.
Publicado: (2023)

Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co‐treatment in pigs with acute ischemic heart failure
por: Rønning, Leif, et al.
Publicado: (2018)

Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects
por: Palaparthy, Rameshraja, et al.
Publicado: (2016)

Myosin with hypertrophic cardiac mutation R712L has a decreased working stroke which is rescued by omecamtiv mecarbil
por: Snoberger, Aaron, et al.
Publicado: (2021)

Fetal Tachyarrhythmia Management from Digoxin to Amiodarone—A Review
por: Gozar, Liliana, et al.
Publicado: (2022)

Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study
por: Lai, Kuan-Cheng, et al.
Publicado: (2018)

Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial
por: Shojaee, Majid, et al.
Publicado: (2017)

Digoxin-amiodarone Combination is Associated With Excess All-cause Mortality in Patients With Atrial Fibrillation
por: Chiang, Jiun-Yang, et al.
Publicado: (2020)

Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats
por: Wang, Qiong, et al.
Publicado: (2019)

A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
por: Trivedi, Ashit, et al.
Publicado: (2022)

Unravelling the complex drug–drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein
por: Ledwitch, Kaitlyn V., et al.
Publicado: (2016)

Warfarin-Amiodarone Drug-Drug Interactions: Determination of [I](u)/K(I),(u) for Amiodarone and its Plasma Metabolites
por: McDonald, MG, et al.
Publicado: (2012)

No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug–Drug Interaction Study
por: Otani, Naoyuki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_73jlg59h49l65om0l9l7so842q